Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Objective: to evaluate the bioavailability of subcutaneous granisetron.Patients receiving
platinum-based chemotherapy will be randomized to receive granisetron 3 mg either
subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine
samples will be collected after each cycle.
Phase:
Phase 2
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra